Loading organizations...
Loading organizations...
Biopharmaceutical company developing targeted drugs for liver disease and c
Terns Pharmaceuticals has raised $167.0M across 2 funding rounds.
Terns Pharmaceuticals has raised $167.0M in total across 2 funding rounds.
Terns Pharmaceuticals has raised $167.0M in total across 2 funding rounds.
Terns Pharmaceuticals's investors include Elise Wang, Eli Lilly and Company, Lilly Asia Ventures, OrbiMed, Samsara BioCapital, Suvretta Capital Management, Vivo Capital, Carl Gordon, Decheng Capital.
Terns Pharmaceuticals has raised $167.0M across 2 funding rounds. Most recently, it raised $87.0M Series C in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 5, 2021 | $87.0M Series C | Elise Wang | Eli Lilly and Company, Lilly Asia Ventures, OrbiMed, Samsara BioCapital, Suvretta Capital Management, Vivo Capital |
| Oct 30, 2018 | $80.0M Series B | Carl Gordon, Vivo Capital | Decheng Capital, Lilly Asia Ventures |